SK6622000A3 - Skin penetration enhancing components - Google Patents

Skin penetration enhancing components Download PDF

Info

Publication number
SK6622000A3
SK6622000A3 SK662-2000A SK6622000A SK6622000A3 SK 6622000 A3 SK6622000 A3 SK 6622000A3 SK 6622000 A SK6622000 A SK 6622000A SK 6622000 A3 SK6622000 A3 SK 6622000A3
Authority
SK
Slovakia
Prior art keywords
formulation
macrocyclic lactone
derivative
macrolide
immunosuppressive macrolide
Prior art date
Application number
SK662-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Anthony David Ormerod
Arthur Winfield
Original Assignee
Univ Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aberdeen filed Critical Univ Aberdeen
Publication of SK6622000A3 publication Critical patent/SK6622000A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
SK662-2000A 1997-11-07 1998-11-05 Skin penetration enhancing components SK6622000A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9723669.9A GB9723669D0 (en) 1997-11-07 1997-11-07 Skin penetration enhancing components
PCT/GB1998/003317 WO1999024036A1 (en) 1997-11-07 1998-11-05 Skin penetration enhancing components

Publications (1)

Publication Number Publication Date
SK6622000A3 true SK6622000A3 (en) 2001-01-18

Family

ID=10821813

Family Applications (1)

Application Number Title Priority Date Filing Date
SK662-2000A SK6622000A3 (en) 1997-11-07 1998-11-05 Skin penetration enhancing components

Country Status (33)

Country Link
US (2) US6958153B1 (no)
EP (2) EP1632231A3 (no)
JP (1) JP2001522801A (no)
KR (1) KR20010031741A (no)
CN (1) CN1115148C (no)
AR (1) AR014011A1 (no)
AT (1) ATE332134T1 (no)
AU (1) AU759326B2 (no)
BG (1) BG104370A (no)
BR (1) BR9815264A (no)
CA (1) CA2309159C (no)
CY (1) CY1105243T1 (no)
DE (1) DE69835163T2 (no)
DK (1) DK1028727T3 (no)
EA (1) EA003616B1 (no)
EE (1) EE04390B1 (no)
ES (1) ES2268795T3 (no)
GB (1) GB9723669D0 (no)
GE (2) GEP20032884B (no)
HR (1) HRP20000233A2 (no)
HU (1) HUP0003675A3 (no)
ID (1) ID24662A (no)
IL (1) IL135978A0 (no)
NO (1) NO20002078L (no)
NZ (3) NZ530752A (no)
PL (1) PL340710A1 (no)
PT (1) PT1028727E (no)
SK (1) SK6622000A3 (no)
TR (1) TR200001238T2 (no)
TW (1) TW557218B (no)
UA (1) UA73274C2 (no)
WO (1) WO1999024036A1 (no)
ZA (1) ZA9810111B (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
CA2413923A1 (en) * 2000-03-09 2001-09-13 Andrew Ilchyshyn Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor
EP1133987A1 (en) * 2000-03-09 2001-09-19 Ian Whitcroft Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor
EP1389209B1 (en) * 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
DK1455888T3 (da) 2001-08-29 2009-08-24 Pharmakodex Ltd Topisk indgivelsesindretning
WO2003049716A1 (en) * 2001-12-13 2003-06-19 Ranbaxy Laboratories Limited Stable topical formulation of clarithromycin
KR20040106547A (ko) * 2002-05-15 2004-12-17 엔도사이트, 인코포레이티드 비타민-마이토마이신 공액체
NZ541846A (en) 2003-01-27 2008-12-24 Endocyte Inc Vitamin receptor binding drug delivery conjugates
AU2004212264B9 (en) * 2003-02-17 2009-11-26 Cipla Limited Pharmaceutical patch
AR043504A1 (es) * 2003-03-17 2005-08-03 Novartis Ag Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
GB0307869D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307865D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US20050079228A1 (en) * 2003-05-30 2005-04-14 Ashish Jaiswal Clear, stable topical compositions of clarithromycin and processes for their preparation
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
WO2005062708A2 (en) * 2003-12-29 2005-07-14 Ramot At Tel-Aviv University Ltd. An assay for the detection of rapamycin and rapamycin analogs
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
US20080207670A1 (en) * 2004-09-16 2008-08-28 Bayer Healthcare Ag Dermally Applicable Formulations For Treating Skin Diseases in Animals
WO2006099359A2 (en) * 2005-03-10 2006-09-21 3M Innovative Properties Company Methods of reducing microbial contamination
CN101175757B (zh) * 2005-03-16 2012-11-14 恩多塞特公司 蝶酸及其缀合物的合成和纯化
EP2382995A3 (en) * 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
BRPI0615354A2 (pt) 2005-08-19 2011-05-17 Endocyte Inc conjugado de liberação de fármaco de ligação de receptor, composição farmacêutica que o compreende, bem como seu uso
US7704959B2 (en) * 2006-10-03 2010-04-27 Dow Pharmaceutical Sciences Azithromycin for the treatment of nodular acne
WO2008063563A2 (en) 2006-11-16 2008-05-29 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mtor inhibitors
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
NZ599239A (en) * 2007-03-14 2013-10-25 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US7919250B2 (en) 2007-07-31 2011-04-05 New York University Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US20100086581A1 (en) * 2008-10-07 2010-04-08 Ernest Bove Method for purpura reduction and prevention
EP2308468A1 (en) * 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
WO2011079154A1 (en) * 2009-12-21 2011-06-30 Sarah Bacus Compositions and methods for treatment of vitiligo
US20120022095A1 (en) * 2010-06-24 2012-01-26 Teng Joyce M C Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis
US20130317053A1 (en) * 2011-01-31 2013-11-28 Osaka University Externally-used drug for treating skin disorder and method for producing same
US20130102572A1 (en) * 2011-04-12 2013-04-25 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
CN102552253A (zh) * 2012-01-17 2012-07-11 唯美度科技（北京）有限公司 一种祛痘用皮肤外用剂
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
IN2015DN04147A (no) 2012-10-16 2015-10-16 Endocyte Inc
AU2014209141B2 (en) * 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
JPWO2015199248A1 (ja) * 2014-06-26 2017-04-27 国立大学法人大阪大学 発汗抑制剤
KR20180081501A (ko) 2015-09-24 2018-07-16 드렉셀유니버시티 진피 장애를 치료하거나 예방하는 신규한 조성물 및 방법
FR3050206B1 (fr) 2016-04-15 2018-05-11 Engie Dispositif et procede d'hydrogenation pour produire du methanol et dispositif et procede de cogeneration de methanol et de methane de synthese
AU2017311491A1 (en) 2016-08-10 2019-02-07 The Board Of Regents Of The University Of Texas System Topical rapamycin therapy
WO2018129364A1 (en) * 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
WO2020010073A1 (en) 2018-07-02 2020-01-09 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE
AU2020226527A1 (en) 2019-02-20 2021-10-14 AI Therapeutics, Inc. Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders
CN116056687A (zh) 2020-03-02 2023-05-02 上海奥科达医药科技股份有限公司 含有mtor抑制剂的外用制剂
FR3112537B1 (fr) 2020-07-14 2023-03-31 Engie Dispositif et procédé de production hybride de dihydrogène de synthèse et/ou de méthane de synthèse
AU2020277132B1 (en) * 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31769A (en) * 1861-03-26 Water-elevator
US3376646A (en) * 1967-03-30 1968-04-09 Herman E. Radke Template tracer
US4335115A (en) * 1976-11-01 1982-06-15 The Procter & Gamble Company Anti-acne composition
US4954487A (en) * 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4299826A (en) * 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
CA1165240A (en) * 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
AU618517B2 (en) 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
US5023085A (en) * 1989-11-29 1991-06-11 Pfizer Inc. Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
CA2033725C (en) * 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
ATE150304T1 (de) 1990-09-04 1997-04-15 Fujisawa Pharmaceutical Co Tricyclische verbindungen enthaltende salben
DK0582239T3 (da) 1992-08-04 1999-12-06 Rhone Poulenc Rorer Gmbh Farmaceutisk og/eller kosmetisk formulering
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
FI90649C (fi) 1993-02-01 1994-03-10 Pauli Groenberg Menetelmä hevosen satulan sovittamiseksi hevosen selkään
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
JPH06345646A (ja) 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
JPH08133979A (ja) * 1994-09-16 1996-05-28 Sando Yakuhin Kk 局所適用薬剤組成物
AU714254B2 (en) 1994-10-26 1999-12-23 Novartis Ag Pharmaceutical compositions
US5648389A (en) * 1995-10-27 1997-07-15 Medicis Pharmaceutical, Inc. Compositions for the treatment of dermatological disorders and methods for their use

Also Published As

Publication number Publication date
NZ530752A (en) 2005-05-27
GB9723669D0 (en) 1998-01-07
ATE332134T1 (de) 2006-07-15
UA73274C2 (en) 2005-07-15
KR20010031741A (ko) 2001-04-16
NZ504076A (en) 2002-12-20
EP1632231A2 (en) 2006-03-08
EE200000279A (et) 2001-10-15
CY1105243T1 (el) 2010-03-03
EA003616B1 (ru) 2003-08-28
ES2268795T3 (es) 2007-03-16
NO20002078D0 (no) 2000-04-19
HUP0003675A2 (hu) 2001-04-28
GEP20043171B (en) 2004-02-25
DE69835163D1 (de) 2006-08-17
HUP0003675A3 (en) 2001-05-28
CA2309159A1 (en) 1999-05-20
EP1632231A3 (en) 2008-01-23
TR200001238T2 (tr) 2001-01-22
GEP20032884B (en) 2003-02-25
HRP20000233A2 (en) 2001-02-28
AU1040899A (en) 1999-05-31
AU759326B2 (en) 2003-04-10
PL340710A1 (en) 2001-02-26
EE04390B1 (et) 2004-12-15
CN1278173A (zh) 2000-12-27
EP1028727B1 (en) 2006-07-05
DE69835163T2 (de) 2007-05-31
NO20002078L (no) 2000-07-06
CN1115148C (zh) 2003-07-23
IL135978A0 (en) 2001-05-20
BG104370A (en) 2000-12-29
US20050239724A1 (en) 2005-10-27
EA200000461A1 (ru) 2000-10-30
US6958153B1 (en) 2005-10-25
JP2001522801A (ja) 2001-11-20
DK1028727T3 (da) 2006-10-23
EP1028727A1 (en) 2000-08-23
CA2309159C (en) 2009-03-17
ZA9810111B (en) 1999-05-07
AR014011A1 (es) 2001-01-31
NZ520449A (en) 2004-04-30
PT1028727E (pt) 2006-11-30
BR9815264A (pt) 2001-08-14
ID24662A (id) 2000-07-27
WO1999024036A1 (en) 1999-05-20
TW557218B (en) 2003-10-11

Similar Documents

Publication Publication Date Title
SK6622000A3 (en) Skin penetration enhancing components
RU2724053C2 (ru) Фармацевтические составы для местного применения для лечения связанных с воспалением состояний
US6180666B1 (en) Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
Ellis et al. Cyclosporine improves psoriasis in a double-blind study
EP0544391A1 (en) Compositions for topical treatment of psoriasis and atopic dermatitis
Yamaguchi et al. Characterization of itch-associated responses of NC mice with mite-induced chronic dermatitis
Gatti et al. Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS
EP1009437A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
Hermann et al. Topical ciclosporin for psoriasis: in vitro skin penetration and clinical study
Birkett et al. Single oral dose pharmacokinetics of erythromycin and roxithromycin and the effects of chronic dosing
Lakritz et al. Pharmacokinetics of erythromycin estolate and erythromycin phosphate after intragastric administration to healthy foals
US20060089406A1 (en) Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases
Yogo et al. Effects of motilin and mitemcinal (GM-611) on gastrointestinal contractile activity in rhesus monkeys in vivo and in vitro
AU2003211175B2 (en) Skin penetration enhancing components
CN115697492A (zh) 一种含有三环杂芳基的化合物的用途
MXPA00004340A (en) Skin penetration enhancing components
AU2006213973A1 (en) Skin penetration enhancing components
CZ20001662A3 (cs) Prostředek pro místní podání
US20070021377A1 (en) Pharmaceutical composition comprising a macrolide immunomodulator
Parsons et al. Effect of recumbency on erythromycin absorption
Pérez et al. Transplacental exchange of moxidectin after maternal or fetal intravenous administration in sheep
Bohlen Effects of ivermectin on antipyrine and erythromycin disposition in cattle
Ghosh REVIEW OF CURRENT LITERATURE
CA2519096A1 (en) Combination of a macrolide t-cell immunomodulator and a calciferol for the treatment of skin diseases or of inflammatory bowel disease